[{"company":"Karolinska Development AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s portfolio company Umecrine Cognition announces results from a phase 2a clinical study of golexanolone","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Karolinska Development AB"},{"company":"Umecrine Cognition","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s Portfolio Company Umecrine Cognition Presents Data from Clinical Phase 2a Study at AALSD International Liver Meeting","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Umecrine Cognition"},{"company":"Karolinska Development AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s Portfolio Company Umecrine Cognition Presents New Data Supporting the Development of Golexanolone as A Treatment of Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Karolinska Development AB"},{"company":"Karolinska Development AB","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Karolinska Development\u2019s Portfolio Company Umecrine Cognition Secures Funding Ahead of Phase 2 Study of Golexanolone in Primary Biliary Cholangitis","therapeuticArea":"Hepatology (Liver, Pancreatic, Gall Bladder)","highestDevelopmentStatus":"Phase II","country":"SWEDEN","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2022","url1":"","url2":"","graph1":"Small molecule","graph2":"Karolinska Development AB"}]
Details:
Results from previous clinical and pre-clinical studies strongly indicate that GR3027 (golexanolone) is able to counteract such inappropriate suppression of brain activity.
Lead Product(s):
Golexanolone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Product Name: GR3027
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 14, 2022
Details:
Golexanolone, a novel drug candidate that counter acts the effect of allopregnanolone on GABAA receptors, thereby restoring normal nerve signalling in the brain.
Lead Product(s):
Golexanolone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Product Name: GR3027
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
November 03, 2021
Details:
Umecrine Cognition will present the results from its recently conducted clinical phase 2a study of the drug candidate golexanonole, that is in clinical development for hepatic encephalopathy.
Lead Product(s):
Golexanolone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Product Name: GR3027
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 02, 2020
Details:
Results demonstrate a positive safety and tolerability profile; however, no indications of clinical effects could be observed.
Lead Product(s):
Golexanolone
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder)
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Small molecule
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 03, 2020
Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
